Intended for healthcare professionals

Letters Covid-19: Equitable global access to vaccines

Ageism in Indonesia’s national covid-19 vaccination programme

BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n299 (Published 02 February 2021) Cite this as: BMJ 2021;372:n299
  1. Peter Lloyd-Sherlock, professor1,
  2. Paramita Muljono, postdoctoral researcher1,
  3. Shah Ebrahim, honorary professor of public health2
  1. 1University of East Anglia, Norwich NR4 7HT, UK
  2. 2London School of Hygiene and Tropical Medicine, London, UK
  1. p.lloyd-sherlock{at}uea.ac.uk

Concern about vaccine nationalism is well founded,1 but it has overshadowed another form of injustice: vaccine ageism.

In many low and middle income countries (LMICs) Sinovac is currently the main covid-19 vaccine. Initial Sinovac trials in China were only conducted on adults aged under 60.2 Because of a lack of published evidence, the government of Indonesia has decided to exclude people aged 60 and over from its initial vaccine rollout.3

Further trials of …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription